The extended 4-year follow-up results of the ELOQUENT-2 trial

Maria Gavriatopoulou; Evangelos Terpos; Meletios A Dimopoulos

doi:10.18632/oncotarget.26527

Back

Shared by

Meletios A Dimopoulos

The extended 4-year follow-up results of the ELOQUENT-2 trial

Editorial Material 2019 en

Authors

MG
Maria Gavriatopoulou
ET
Evangelos Terpos
Meletios A Dimopoulos

Related publications

Article2018

Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)

Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece,

Discussion(0)

Sign in to like and join the discussion.

No comments yet. Be the first to comment.

Meral Beksaç,

Suresh G. Shelat,

Oumar Sy,

Anil Singhal,

Paul G. Richardson

Article2017

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Sabeen Mekan, Oumar Sy, Anil Singhal, Paul G. Richardson

Article1995

792-1 One Year Clinical Follow-up of the Benestent Trial

Carlos Macaya, Patrick W. Serruys, Harry Suryapranata, Gijs Mast, Silvio Klugmann, Philip Urban, Peter den Heijer, Jan J. Piek, Rüdiger Simon, M.C. Morice, Peter Crean, J. J. R. M. Bonnier, William Wijns, N Danchin, C Bourdonnec

Journal of the American College of Cardiology

Article2014

P.2.d.044 Functional remediation in bipolar disorder: results of the one-year follow-up

Carla Torrent, Caterina del Mar Bonnín, Anabel Martínez‐Arán, Celso Arango, Benedikt L. Amann, Brisa Solé, Ana González‐Pinto, José Manuel Crespo, Rafael Tabarés‐Seisdedos, María Reinares, José Ramón Tejera del Valle, María Paz García‐Portilla, Ángela Ibáñez, Eduard Vieta

Article2018

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Suresh G. Shelat, Oumar Sy, Anil Singhal, Paul G. Richardson